Citizens raises OptimizeRx stock price target on macro stability
Citizens has increased its price target for OptimizeRx (NASDAQ: OPRX) shares to $11.00 from $9.00, maintaining a Market Outperform rating. The upward revision is attributed to a more stable macroeconomic environment and the anticipated return of a major customer in late 2026 or 2027, alongside continued momentum in mid-tier biopharmas. The new target reflects an 8x 2026 EBITDA multiple, up from 7x, based on improved conviction in future financial estimates and the company's strategic initiatives.
OptimizeRx Corp (OPRX) gains 6.7% institutional holder in Kennedy Capital
Kennedy Capital Management LLC has reported a beneficial ownership of 1,248,899 shares of OptimizeRx Corp (OPRX) common stock, representing a 6.7% stake. The firm, based in St. Louis, Missouri, holds sole voting and dispositive power over these shares, establishing itself as a significant institutional investor in OptimizeRx. This disclosure was made through a Schedule 13G filing, indicating a passive investment.
Citizens raises OptimizeRx stock price target on macro stability
Citizens has increased its price target for OptimizeRx (NASDAQ:OPRX) to $11.00 from $9.00, maintaining a Market Outperform rating. This adjustment is based on a stabilizing macro environment, the potential return of a large customer, and momentum in mid-tier biopharma. The new target reflects an 8x 2026 EBITDA multiple, up from 7x, with the company’s DSP strategy and new solutions expected to drive growth in 2027.
Renaissance Technologies LLC Has $1.36 Million Stock Position in OptimizeRx Corp. $OPRX
Renaissance Technologies LLC significantly increased its stake in OptimizeRx Corp. (NASDAQ:OPRX) by 633.2% in the first quarter, now holding 216,856 shares valued at $1.36 million. OptimizeRx reported strong Q2 earnings, beating analyst estimates with $0.16 EPS and $20.5 million in revenue, and maintained its 2026 revenue guidance. Despite some revenue headwinds and a CFO transition, analysts have a "Moderate Buy" rating with an average price target of $13.14.
Stifel cuts OptimizeRx stock price target on revenue headwinds
Stifel has lowered its price target for OptimizeRx (NASDAQ:OPRX) to $12 from $14, while maintaining a Buy rating, due to revenue headwinds. OptimizeRx reported a 30% year-over-year revenue decline in Q2, attributed to client-specific issues, de-emphasis of acquired services, and macro challenges, though EBITDA margins expanded. The company reiterated its 2026 guidance for a low-double-digit revenue decline and mid-20s EBITDA margins, suggesting a transition year with anticipated sequential growth in the second half.
OptimizeRx (OPRX) revenue falls 21% as margins and cash flow hold
OptimizeRx (OPRX) reported a significant revenue decline of 21% year-to-date and 30% in Q2 2026, primarily due to the wind-down of a low-margin managed service program and the loss of revenue from a key customer. Despite this, the company improved its gross margin by shifting towards higher-margin solutions and maintained strong operating cash flow of $8.1 million in the first half of 2026. OptimizeRx also refinanced its debt, enhancing liquidity, but still faces a material weakness in internal control related to third-party data.
Stifel cuts OptimizeRx stock price target on revenue headwinds
Stifel has lowered its price target for OptimizeRx (NASDAQ: OPRX) to $12 from $14, while maintaining a Buy rating, due to significant revenue headwinds. The company reported a 30% year-over-year revenue decline in Q2 2026, though adjusted earnings per share exceeded expectations. OptimizeRx reiterated its 2026 guidance for a low-double-digit revenue decline, with analysts expecting a sales drop of 11% for the fiscal year.
OptimizeRx Announces Finance Leadership Appointments to Support the Next Phase of Growth
OptimizeRx Corporation has announced key finance leadership changes, effective January 1, 2027. Andy D'Silva will become the new Chief Financial Officer, succeeding Ed Stelmakh, who will transition to a Strategic Advisor role. Heather Favazza has been appointed Chief Accounting Officer, reflecting the company's strong succession planning and confidence in its long-term strategy.
OptimizeRx Announces Finance Leadership Appointments to Support the Next Phase of Growth
OptimizeRx has announced significant finance leadership appointments, effective January 1, 2027, as part of its succession planning. Andy D’Silva will take over as Chief Financial Officer, succeeding Ed Stelmakh, who will transition to a Strategic Advisor role. Heather Favazza has been appointed Chief Accounting Officer, reflecting the company's strong leadership bench and continued focus on financial rigor and growth strategy.
OptimizeRx Corp (OPRX) (Q2 2026) Earnings Call Highlights: Navigating Revenue Headwinds with ...
OptimizeRx Corp (OPRX) reported a 30% year-over-year revenue decrease in Q2 2026, reaching $20.5 million, with adjusted EBITDA falling to $4.1 million. Despite these revenue headwinds, the company exceeded consensus expectations, driven by strong growth in AI-enabled software and product innovations. OptimizeRx reaffirmed its full-year 2026 guidance, focusing on debt reduction, strategic product launches, and expanding into new market segments to drive future growth.
OptimizeRx Reports Second Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance
OptimizeRx Corp. announced its second-quarter 2026 financial results, reporting $20.5 million in revenue and reaffirming its fiscal year 2026 revenue guidance of $95 million to $100 million. The company also highlighted strategic platform advancements, including integrations with DeepIntent, the launch of Natural Language Audience Builder, and CopayCue, alongside significant debt reduction efforts. Despite a year-over-year revenue decrease, OptimizeRx expressed confidence in its operating model and future growth opportunities.
OptimizeRx names Andy D’Silva as CFO, Heather Favazza as CAO
OptimizeRx Corp. (NASDAQ:OPRX) has appointed Andy D’Silva as Chief Financial Officer and Heather Favazza as Chief Accounting Officer, effective January 1, 2027. D’Silva will succeed Ed Stelmakh, who transitions to a Strategic Advisor role after serving as CFO for five years during which the company expanded margins, refinanced debt, and completed an acquisition. The company stated this transition is part of its succession planning and its financial and growth strategy remains unchanged.
Earnings call transcript: OptimizeRx beats Q2 2026 profit view as shares slip
OptimizeRx Corp. reported Q2 2026 adjusted earnings of $0.16 per share, surpassing the $0.10 consensus, and revenue of $20.5 million, above the $20.19 million expectation. Despite beating profit views, the stock slipped after hours due to a 30% year-over-year revenue decline and continued pressure from large customer spending cuts. Management reaffirmed full-year 2026 guidance, expecting a stronger second half, and highlighted strategic shifts towards a broader platform for pharmaceutical marketers and increased recurring software revenue.
OptimizeRx Corp. (OPRX) Q2 Earnings and Revenues Top Estimates
OptimizeRx Corp. (OPRX) exceeded Q2 earnings and revenue estimates, reporting $0.16 per share against an expected $0.11, and revenues of $20.5 million, slightly above the consensus. Despite these positive results, the company's shares have underperformed the S&P 500 this year, with a Zacks Rank of #3 (Hold) indicating market-aligned performance in the near future. Investors are now looking to management's earnings call commentary and future estimate revisions for insights into the stock's direction.
OptimizeRx CFO Ed Stelmakh Will Advise Through End of 2027
OptimizeRx (Nasdaq: OPRX) announced a planned finance leadership transition with Andy D’Silva appointed as the new Chief Financial Officer and Heather Favazza as Chief Accounting Officer, both effective January 1, 2027. Current CFO Ed Stelmakh will continue in his role through December 31, 2026, and then serve as a Strategic Advisor through the end of 2027 to ensure a smooth transition and continuity. The company credits Stelmakh with significant financial improvements and emphasizes that its financial and growth strategy remains unchanged.
OptimizeRx Reports Second Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance
OptimizeRx announced its second-quarter 2026 financial results, reporting $20.5 million in revenue and a GAAP net loss of $(0.7) million. Despite a year-over-year revenue decline, the company exceeded consensus expectations for revenue and adjusted EBITDA, which stood at $4.9 million. OptimizeRx reaffirmed its fiscal year 2026 revenue guidance of $95-$100 million and adjusted EBITDA guidance of $21-$25 million, citing recent platform advancements and strengthened customer engagement.
OptimizeRx (OPRX) Q2 2026 revenue falls 30% but company reaffirms full-year outlook
OptimizeRx (OPRX) reported a 30% decrease in Q2 2026 revenue to $20.5 million and a GAAP net loss of $0.7 million, down from a net income of $1.5 million in Q2 2025. Despite the revenue decline and lower net revenue retention, the company reaffirmed its full-year 2026 guidance for revenue between $95-$100 million and adjusted EBITDA of $21-$25 million. OptimizeRx also announced a finance leadership transition, with Edward Stelmakh stepping down as CFO and Andy D’Silva and Heather Favazza taking over as CFO and Chief Accounting Officer, respectively, effective January 1, 2027.
Earnings To Watch: OptimizeRx Corp (OPRX) Q2 2026 -- GF Value Sees 106% Upside
OptimizeRx Corp (OPRX) is expected to release its Q2 2026 earnings soon, with consensus estimates predicting $20.20 million in revenue and an earnings per share of -$0.05. Despite recent declines in revenue and earnings estimates for 2026, analysts and GuruFocus see significant upside potential, with an average target price of $12.40 and a GF Value suggesting a 106.13% upside. The company's average brokerage recommendation is "Outperform."
OptimizeRx Set to Report Q2 2026 Results With Analyst Targets Pointing to Over 80% Upside
OptimizeRx Corp (OPRX) is scheduled to report its Q2 2026 earnings on August 12, with analysts expecting revenue of $20.20 million and a loss of $0.05 per share. Despite recent downward revisions in full-year revenue estimates and a significant stock drop after its Q1 beat, analysts maintain a bullish outlook, with price targets suggesting an 81% to 106% upside. Investors will be watching for Q2 results and full-year guidance to see if the company can close the gap between its trading price and its perceived intrinsic value.
OptimizeRx Corp (OPRX) Earnings Forecast: Future EPS & Revenue Growth Estimates
OptimizeRx Corp (OPRX) has an earnings forecast score of 8.67, ranking 26th in the Software & IT Services industry. Analysts project an average price target of $24.00, with a consensus "Buy" rating based on 6 analysts. The company's expected revenue for the next quarter is $20.20 million, and its EPS for the next quarter is anticipated to be $0.12.
OptimizeRx Corp (OPRX) Stock News Today
This article provides current stock information for OptimizeRx Corp (OPRX), including its latest stock price, market capitalization, and P/E ratio. It indicates that more news and analysis for OPRX will be published soon.
Segall Bryant & Hamill LLC Invests $1.19 Million in OptimizeRx Corp. $OPRX
Segall Bryant & Hamill LLC has invested $1.19 million in OptimizeRx Corp. (NASDAQ: OPRX), acquiring 188,704 shares, which gives them a 1.01% stake in the company. Institutional investors now collectively own 76.47% of OptimizeRx, which recently exceeded quarterly earnings and revenue expectations. Analysts generally maintain a "Moderate Buy" rating for OptimizeRx, with an average price target of $13.43 despite some recent reductions.
OptimizeRx Corp. (NASDAQ:OPRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages
OptimizeRx Corp. (NASDAQ:OPRX) has received a consensus "Moderate Buy" rating from brokerages, with six out of nine analysts recommending a buy, two a hold, and one a sell. The average 12-month price target is $13.43, despite several firms recently lowering their targets. The company reported strong quarterly earnings, beating consensus estimates for both EPS and revenue.
Optimizerx Stock Price Forecast. Should You Buy OPRX?
StockInvest.us has upgraded OptimizeRx Corporation (OPRX) to a "Buy Candidate" with a technical score of 2.73, up from a "Hold." The stock price increased by 8.26% on the last trading day, reaching $6.55, and is forecasted to rise 16.87% over the next three months. Despite some mixed signals like a recent pivot top and falling volume on increasing price, the stock holds positive buy signals from both short and long-term Moving Averages.
OptimizeRx Corp (OPRX) Valuation: PE, PB & Fair Value Analysis
This article analyzes the valuation of OptimizeRx Corp (OPRX) using key financial metrics. As of July 31, 2026, OPRX has a valuation score of 8.04, placing it 219th in the Software & IT Services industry, with a P/E ratio of 16.38. The article notes that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
OptimizeRx Corp (OPRX) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for OptimizeRx Corp (OPRX), highlighting its current risk score of 4.19 and its beta of 1.14 against the S&P 500. It details various risk metrics including volatility, maximum drawdown, and Sharpe Ratio over different periods. The assessment suggests OPRX tends to outperform in upward markets but experiences larger declines in downward trends.
OptimizeRx Corp (OPRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of OptimizeRx Corp (OPRX), focusing on its current stock price momentum, support and resistance levels, and various technical indicators and moving averages. It notes that OPRX's current price momentum score is 3.51, and the stock is trading between a resistance level of 6.80 and a support level of 5.82. The analysis also includes a breakdown of indicator signals (MACD, RSI, etc.) and moving average signals, with an overall "Neutral" signal based on these factors.
OptimizeRx Sets Second Quarter 2026 Conference Call for August 12, 2026, at 4:30 p.m. ET
OptimizeRx Corp. (Nasdaq: OPRX) has announced a conference call to discuss its second-quarter 2026 financial results. The call is scheduled for Wednesday, August 12, 2026, at 4:30 p.m. Eastern Time. Financial results will be released via press release prior to the call, which will include a management discussion and a Q&A session.
BlackRock (OPRX) discloses 342,250 OptimizeRx shares held with sole voting power
BlackRock, Inc. has filed an amendment (Schedule 13G/A) disclosing its beneficial ownership in OptimizeRx Corp (OPRX). As of June 30, 2026, BlackRock's reporting business units beneficially owned 342,250 shares of OptimizeRx common stock, representing 1.8% of the class. BlackRock reports having sole voting and sole dispositive power over all these shares, with no individual client holding more than five percent of OptimizeRx's outstanding common shares.
OptimizeRx Sets Second Quarter 2026 Conference Call for August 12, 2026, at 4:30 p.m. ET
OptimizeRx will host a conference call on Wednesday, August 12, 2026, at 4:30 p.m. Eastern Time to discuss its financial results for the second quarter ended June 30, 2026. Financial results will be released via press release before the call, which will include a question-and-answer session with management. Details for accessing the call via telephone or webcast are provided, and a replay will be available on the company's investor website.
Management will take questions after OptimizeRx releases Q2 results
OptimizeRx (Nasdaq: OPRX) has announced it will host a conference call on Wednesday, August 12, 2026, at 4:30 p.m. ET to discuss its financial results for the second quarter ended June 30, 2026. The results will be released in a press announcement prior to the call, and management will host a question-and-answer period. Investors can join the call via toll-free phone, international phone, or webcast, with a replay available for 12 months on the company's website.
OptimizeRx Market Sentiment
This article provides an overview of OptimizeRx (OPRX) market sentiment, focusing on analyst consensus, short interest, options flow, and insider activity. It highlights a "Buy" consensus from 11 analysts with an average price target of $13, and notes declining short interest and bullish options flow. The report also includes a detailed table of recent analyst actions, including price target changes and rating adjustments.
OptimizeRx Corp (OPRX) Financial Health: Profitability & Balance Sheet Analysis
OptimizeRx Corp (OPRX) has a strong financial health score of 7.50, ranking 194th in the Software & IT Services industry. While its financial status is robust, operational efficiency is average, with recent quarterly revenue and net profit showing year-over-year decreases of 9.50% and 77.49% respectively. The article provides an overview of various financial dimensions like quality of earnings, operational efficiency, growth potential, and shareholder returns, noting that relevant data for these metrics have not yet been disclosed by the company.
OptimizeRx Corp (OPRX) Cash Flow
This article provides a comprehensive cash flow statement for OptimizeRx Corp (OPRX), detailing quarterly and annual data for operating, investing, and financing cash flows. It includes key financial metrics like net income, capital expenditures, and free cash flow, along with year-over-year percentage changes. The article also features an FAQ section to explain cash flow concepts and OptimizeRx Corp's performance in these areas, making it a valuable resource for evaluating the company's financial health.
OptimizeRx Corp (OPRX) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of OptimizeRx Corp's (OPRX) dividend and stock split history. It notes that the company has not distributed any dividends over the past five years. The page displays key financial data for OptimizeRx Corp, including its market cap and P/E ratio.
OPRX|OptimizeRx Corp|Price:6.375|Chg%:+0.135
This article provides a detailed company profile of OptimizeRx Corporation (OPRX), a healthcare technology company. It highlights the company's AI-driven platform for patient engagement, including its Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT). The report also lists key company information, financial data, executive leadership, and institutional shareholding details.
OptimizeRx Corp (OPRX) Shareholder Structure: Major Shareholders & Institutional Holdings
This article provides a detailed breakdown of the shareholder structure for OptimizeRx Corp (OPRX), including major individual and institutional holders and their respective proportions. It also details institutional shareholding trends over recent quarters, changes in specific institutional holdings, and lists related ETFs that include OPRX.
OptimizeRx Corp (OPRX) Earnings Forecast: Future EPS & Revenue Growth Estimates
OptimizeRx Corp (OPRX) has an earnings forecast score of 8.67, ranking it 25th in the Software & IT Services industry. The company has an average price target of $24.00, with analysts largely recommending a "Buy." Expected revenue for the next quarter is $20.20M, and the EPS is projected to be $0.12.
OptimizeRx appoints Sarah Bast as chief marketing officer
OptimizeRx Corp. has appointed Sarah Bast as its new Chief Marketing Officer. Bast brings over 20 years of pharmaceutical marketing experience, having previously worked at Publicis Health Media and guided marketing strategies for major life sciences companies like Lilly and Johnson & Johnson. In her new role, she will lead OptimizeRx's marketing strategy and strengthen relationships with healthcare marketing agencies and life sciences teams.
OptimizeRx Corp (OPRX) Institutional Confidence
OptimizeRx Corp (OPRX) has an institutional shareholding score of 7.00, ranking 139th out of 485 in the Software & IT Services industry. The institutional shareholding proportion recently increased by 8.32% quarter-over-quarter to 82.46%. The largest institutional shareholder is Bill Nygren | OAKMX, holding 1.14M shares, representing 4.73% of shares outstanding after a 3841.67% increase in holdings.
OPRX|OptimizeRx Corp|Price:6.240|Chg%:+0.030
OptimizeRx Corp (OPRX) shows strong fundamentals and high growth potential, with its valuation deemed fairly valued within the Software & IT Services industry. Analysts have rated it a "Buy" with a target price of $12.40. While the stock has seen strong market performance, technical indicators suggest a stable, sideways trading pattern.
OptimizeRx Appoints Veteran Point of Care Marketing Leader Sarah Bast as Chief Marketing Officer
OptimizeRx Corp. (Nasdaq: OPRX) has appointed Sarah Bast as its new Chief Marketing Officer. Bast brings over two decades of pharmaceutical marketing experience, including specialized expertise in point of care media strategy, and will lead OptimizeRx's marketing strategy, brand positioning, and go-to-market initiatives. Her appointment aims to strengthen relationships with healthcare marketing agencies and life sciences teams, supporting continued product innovation and commercial growth for the company.
OptimizeRx appoints Sarah Bast as chief marketing officer
OptimizeRx Corp. (NASDAQ:OPRX) has announced the appointment of Sarah Bast as its new Chief Marketing Officer. Bast brings over 20 years of pharmaceutical marketing experience, previously serving as EVP at Publicis Health Media, and will lead OptimizeRx's marketing strategy and strengthen relationships with healthcare marketing agencies and life sciences teams.
Press Release: OptimizeRx Appoints Veteran Point of Care Marketing Leader Sarah Bast as Chief Marketing Officer
OptimizeRx, a company specializing in healthcare technology and digital health solutions, has announced the appointment of Sarah Bast as its new Chief Marketing Officer (CMO). Bast brings over 20 years of experience in point-of-care marketing and will be responsible for enhancing OptimizeRx's brand presence and market leadership. Her appointment is expected to strengthen the company's ability to connect life sciences companies with healthcare providers and patients.
Press Release: OptimizeRx Appoints Veteran Point of Care Marketing Leader Sarah Bast as Chief Marketing Officer
OptimizeRx, a company specializing in delivering pharmaceutical information to healthcare providers and patients, has announced the appointment of Sarah Bast as its new Chief Marketing Officer. Bast previously served as Senior Vice President of Marketing and Content at Point-of-Care Health Media. Her appointment is expected to bolster OptimizeRx's market leadership in digital health solutions.
OptimizeRx appoints Sarah Bast as chief marketing officer By Investing.com
OptimizeRx Corp. (NASDAQ:OPRX) announced the appointment of Sarah Bast as Chief Marketing Officer. Bast brings over 20 years of pharmaceutical marketing experience, having previously served as Executive Vice President at Publicis Health Media and guided marketing strategy for major life sciences companies. In her new role, she will lead OptimizeRx's marketing strategy, brand positioning, and go-to-market initiatives, focusing on strengthening relationships with healthcare marketing agencies and life sciences teams.
Sarah Bast Brings More Than Two Decades of Pharma Marketing to OptimizeRx
OptimizeRx (Nasdaq: OPRX) has appointed Sarah Bast as its new Chief Marketing Officer, effective July 23, 2026. Bast brings over two decades of experience in pharmaceutical marketing, specializing in point of care media strategy, analytics, and optimization. In her new role, she will lead OptimizeRx's marketing strategy, brand positioning, and go-to-market initiatives, aiming to strengthen relationships within the healthcare industry and support product innovation.
OptimizeRx Appoints Veteran Point of Care Marketing Leader Sarah Bast as Chief Marketing Officer
OptimizeRx Corporation has appointed Sarah Bast as Chief Marketing Officer, bringing over two decades of pharmaceutical marketing experience to their leadership team. Bast, previously Executive Vice President at Publicis Health Media, will lead OptimizeRx's marketing strategy, brand positioning, and go-to-market initiatives to strengthen partnerships and drive innovation in the life sciences industry. Her expertise in point-of-care media and healthcare marketing aims to enhance how life science brands engage with healthcare professionals and patients.
Royce & Associates (OPRX) discloses 1.09M-share passive stake in OptimizeRx
Royce & Associates, LP has disclosed a passive stake of 1,089,398 shares in OptimizeRx Corp (OPRX), representing 5.81% of the company's common stock as of June 30, 2026. Royce & Associates, an indirect majority-owned subsidiary of Franklin Resources, Inc., holds this position for its investment management clients and asserts sole voting and dispositive power over these shares. The firm states that this holding is in the ordinary course of business and is not intended to influence control of OptimizeRx.
OptimizeRx Corp. (NASDAQ:OPRX) Sees Significant Decline in Short Interest
OptimizeRx Corp. (NASDAQ:OPRX) experienced a significant 39% decrease in short interest in June, bringing the total short interest to 1,129,328 shares. The company's stock rose 2.0% to $6.78, and its recent earnings exceeded expectations with an EPS of $0.14 against a $0.01 consensus. Analysts generally maintain a "Moderate Buy" rating with an average price target of $13.43.
